Latest / Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio / Why Pfizer Is the Contrarian Dividend Play of 2026
Transcript
- Lucas: So Pfizer is up nearly seven percent over the last five days, and it's not because of some meme-stock frenzy. The stock is at twenty-six seventy-six, and the market is starting to ask if this is the beginning of a real turnaround. Luna: Seven percent in a week for a mega-cap pharma? That's not nothing. What's driving it? Lucas: A few things. The July jobs miss has traders betting the Fed won't hike in September, and that's taking some pressure off rate-sensitive names. But there's also a specific catalyst: a couple of analysts have upgraded the stock, pointing to the pipeline and the potential for a dividend hike next year. Lucas: Look, I know we've talked a lot about the AI trade and tech selloffs, but this feels like a different kind of story. It's about a company that's been beaten down for years, and now there's a real argument that the worst is over. Luna: Before we go deeper, I have to say — if this conversation helps you think about your own portfolio, consider buying me a coffee. It's buy me a coffee dot com slash fexingo. That's the whole ask. Lucas: Yeah, honestly, it's how we keep the show ad-free and independent. No pressure, but if you get value from these episodes, that's the link. Luna: Alright, back to Pfizer. What's the bear case you're wrestling with? Lucas: The bear case is the patent cliff. A bunch of blockbusters — including the COVID vaccine and the antiviral — have lost exclusivity, and revenue has fallen hard. The market's been treating it like a melting ice cube. Luna: Right, but that's been priced in for a while. What's changed? Lucas: Two things. First, the pipeline is starting to deliver. There's a new obesity drug candidate that's in late-stage trials, and that's a huge addressable market. Second, management has been cutting costs aggressively, and that's starting to show up in the bottom line. Luna: So you're saying the worst of the revenue decline might be behind them? Lucas: That's the bull thesis. And the dividend yield is still over five percent, which is pretty attractive if you think the payout is safe. The company generated enough free cash flow to cover the dividend even during the trough, and they've got a strong balance sheet. Luna: But isn't a high yield sometimes a red flag? If the market thinks the dividend could be cut, the yield spikes. Lucas: Exactly. And that's the key question. Is the market pricing in a realistic probability of a cut, or is this a mispricing? The consensus seems to be that a cut isn't imminent, but it's not off the table either. Luna: How do you think about that in a concentrated portfolio? You don't want to blow up your income stream. Lucas: Right. If you're building a concentrated portfolio, you're not looking for a hundred names. You're looking for your best ideas. Pfizer could be one of those if you believe the pipeline is underappreciated and the dividend is safe. But you have to size it appropriately. Lucas: I'd say it's a complement to a growth-heavy portfolio. It gives you defensive characteristics and income, which is useful when there's rotation happening. Luna: So what would you look for as confirmation that the turnaround is real? Lucas: First, I'd watch for data from the obesity trial. If that shows positive results, that's a game-changer. Second, I'd look at the next couple of earnings reports to see if the cost cuts are translating into margin expansion. And third, any commentary on the dividend from management — if they signal a hike, that's a strong signal. Luna: How does Pfizer fit into the broader market rotation we've been seeing? Tech is down, but pharma has been kind of quiet. Lucas: That's a good point. The S&P is up two percent over the last five days, but the action has been very tech-heavy. NVIDIA is up eight percent. Alphabet is down five percent. There's a lot of dispersion. Meanwhile, Pfizer is up seven percent, and it's not because of the AI trade. Lucas: When you see that kind of divergence, it tells me some money is rotating into beaten-down value names with real cash flows. Luna: So you're saying this could be the start of a broader value rotation? Lucas: I'm cautious about calling a full rotation, but the ingredients are there. The Fed might be done hiking, rates could come down, and that tends to help value and dividend stocks. Plus, you have these high-quality names trading at deep discounts. Pfizer trades at about twelve times forward earnings, which is cheap for a company with its pipeline. Luna: That's tempting, but I keep thinking about opportunity cost. Why not just stick with the tech winners that are still going up? Lucas: Because valuations matter. When you pay up for growth, you're assuming a lot of good news. With Pfizer, you're getting a defensive business with a big dividend, and the upside is if the pipeline hits. That's a better risk-reward for a lot of investors right now, especially with the market at record highs. Lucas: And the S&P is at seventy-seven hundred, which is up twenty-one percent over five days. That's a lot of optimism priced in. Having some defensive exposure isn't a bad idea. Luna: So what's your takeaway for people listening? If they're thinking about adding Pfizer, what should they do? Lucas: I'd say don't chase the seven percent jump. Wait for a pullback or a dip, and start a small position. Use the dividend to get paid while you wait. And keep an eye on the pipeline catalysts. If the obesity drug works, this stock could re-rate significantly. Luna: That sounds like a prudent approach. I’m curious to see how the next earnings call goes. Lucas: Absolutely. It's a stock that rewards patience, and in a market that's been all about speed, that's refreshing.